Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques

Clinical and Diagnostic Laboratory Immunology

Volumn 4, Issue 1, 1997, Pages 107-111

  Ohlin, Mats ^a   Silvestri, Michel ^b   Sundqvist, Vivi Anne ^b   Borrebaeck, Carl A K ^a  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; VIRUS GLYCOPROTEIN;

ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL;

EID: 0031048071     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.4.1.107-111.1997     Document Type: Article

References (27)

1. Adler, S. P. 1996. Current prospects for immunization against cytomegalovirus disease. Infect. Agents Dis. 5:29-35.
2. Balachandran, N., D. E. Oba, and L. M. Hutt-Fletcher. 1987. Antigenic cross-reactions among herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus. J. Virol. 61:1125-1135.
3. Britt, W. J., L. Vugler, E. J. Butfiloski, and E. B. Stephens. 1990. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J. Virol. 64:1079-1085.
4. Chou, S., and G. I. Marousek. 1992. Homology of the envelope glycoprotein B of human herpesvirus-6 and cytomegalovirus. Virology 191:523-528.
5. Goade, D. E., R. Bell, T. Yamada, G. J. Mertz, and S. Jenison. 1996. Locations of herpes simplex virus type 2 glycoprotein B epitopes recognized by human serum immunoglobulin G antibodies. J. Virol. 70:2950-2956.
6. Gōnczōl, E., K. Berencsi, S. Pincus, V. Endresz, C. Méric, E. Paoletti, S. A. Plotkin. 1995. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 13:1080-1085.
7. Kniess, N., M. Mach, J. Fay, and W. J. Britt. 1991. Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. J. Virol. 65:138-146.
8. Kropff, B., M.-P. Landini, and M. Mach. 1993. An ELISA using recombinant proteins for the detection of neutralizing antibodies against human cytomegalovirus. J. Med. Virol. 39:187-195.
9. Li, S., and J. E. Cronan, Jr. 1992. The gene encoding the biotin carboxylase subunit of Escherichia coli acetyl-CoA carboxylase. J. Biol. Chem. 267:855-863.
10. Matsuzawa, K., T. Koyama, S. Sugawara, S. Ikegawa, S. Asano, S. Sasaki, T. Tomijama, Y. Kasahara, Y. Okamiya, K. Inoue, T. Ohta, and T. Makita. 1992. The preclinical safety evaluation of human monoclonal antibody against cytomegalovirus. Fundam. Appl. Toxicol. 19:26-32.
11. Meyer, H., Y. Masuho, and M. Mach. 1990. The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope. J. Gen. Virol. 71:2443-2450.
12. Meyer, H., V.-A. Sundqvist, L. Pereira, and M. Mach. 1992. Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. J. Gen. Virol. 73:2375-2383.
13. Ohlin, M., and C. A. K. Borrebaeck. 1996. Low affinity antibody binding of an Escherichia coli-derived component. FEMS Immunol. Med. Microbiol. 13:161-168.
14. Ohlin, M., H. Owman, M. Mach, and C. A. K. Borrebaeck. 1996. Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Mol. Immunol. 33:47-56.
15. Ohlin, M., V.-A. Sundqvist, G. Gilliam, U. Rudén, F. O. Gombert, B. Wahren, and C. A. K. Borrebaeck. 1991. Characterization of human monoclonal antibodies directed against the pp65 KD matrix antigen of human cytomegalovirus. Clin. Exp. Immunol. 84:508-514.
16. Ohlin, M., V.-A. Sundqvlst, M. Mach, B. Wahren, and C. A. K. Borrebaeck. 1993. Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J. Virol. 67:703-710.
17. Pass, R. F., A.-M. Duliege, S. B. Boppana, W. J. Britt, D. M. Granoff, R. Sekulovich, and R. L. Burke. 1995. Immunogenicity of a recombinant CMV gB vaccine. Pediatr. Res. 37:185A.
18. Plotkin, S. A. 1994. Vaccines for varicella-zoster virus and cytomegalovirus: recent progress. Science 265:1383-1385.
19. Riddell, S. R., K. S. Watanabe, J. M. Goodrich, C. R. Li, M. E. Agha, and P. D. Greenberg. 1992. Restoration of viral immunity in immunodeficient humans by adoptive transfer of T cell clones. Science 257:238-241.
20. Sällberg, M., U. Rudén, L, O. Magnius, E. Norrby, and B. Wahren. 1991. Rapid "tea-bag" peptide synthesis using 9-fiuorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol. Lett. 30:59-68.
21. Schoppel, K., E. Haßfurther, W. Britt, M. Ohlin, C. A. K. Borrebaeck, and M. Mach. 1996. Antibodies specific for the antigenic determinant 1 (AD-1) of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. Virology 216:133-145.
22. Silvestri, M. E., M. Brytting, G. Hedengrahn, and V.-A. Sundqvist. The major epitope of CMV gpULSS expressed as an in vivo biotinylated fusion protein. Submitted for publication.
23. Silvestri, M., F. Jäderling, U. Rudén, M. Ohlin, and V.-A. Sundqvist. 1993. Fine specificity and neutralizing activity of human serum antibodies directed to the major antigenic region on gp116 of human cytomegalovirus. Serodiagn. Immunother. Infect. Dis. 5:209-216.
24. Spaete, R. R., R. C. Gehrz, and M. P. Landini. 1994. Human cyomegalovirus structural proteins. J. Gen. Virol. 75:3287-3308.
25. Sundqvist, V.-A., and B. Wahren. 1981. An interchangeable ELISA for cytomegalovirus antigen and antibody. J. Virol. Methods 1:301-312.
26. Utz, U., W. Britt, L. Vugler, and M. Mach. 1989. Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. J. Virol. 63:1995-2001.
27. Yang, H., J. K. Leland, D. Yost, and R. J. Massey. 1994. Electrochemiluminescence: a new diagnostic and research tool. Bio/Technology 12:193-194.